Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)
| العنوان: | Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study) |
|---|---|
| المؤلفون: | Yasushi Tanaka, Ryusuke Koshida, Masayuki Senda, Takahisa Hirose, Yasuo Terauchi, Masato Odawara, Munehide Matsuhisa |
| المصدر: | Expert Opinion on Pharmacotherapy. 22:249-256 |
| بيانات النشر: | Informa UK Limited, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, Pediatrics, medicine.medical_specialty, endocrine system diseases, Insulin Glargine, Postmarketing surveillance, 03 medical and health sciences, 0302 clinical medicine, Japan, Product Surveillance, Postmarketing, Humans, Hypoglycemic Agents, Medicine, Basal insulin, Pharmacology (medical), Prospective Studies, Aged, Glycated Hemoglobin, Pharmacology, Type 1 diabetes, Dose-Response Relationship, Drug, business.industry, Insulin glargine, nutritional and metabolic diseases, General Medicine, Middle Aged, medicine.disease, Hypoglycemia, post-marketing surveillance study, Diabetes Mellitus, Type 1, 030220 oncology & carcinogenesis, Japanese, Female, business, Real world data, type 1 diabetes mellitus, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | Background: With limited real-world insulin glargine 300 U/mL (Gla-300) data among Japanese patients with type 1 diabetes mellitus (T1DM) available, the authors describe its effectiveness and safety in Japanese T1DM patients switching to Gla-300. Research design and methods: X-STAR was a 12-month prospective, observational, post-marketing study in Japanese patients with diabetes mellitus from 2015 to 2018: insulin-experienced T1DM patients initiating Gla-300 were analyzed. Results: Of 774 patients, mean (±standard deviation) HbA1c (%) and fasting plasma glucose (mg/dL) decreased from 8.27 ± 1.55 to 8.15 ± 1.35 (by −0.12 ± 1.30 [p = 0.013]) and 167.9 ± 92.6 to 153.9 ± 70.9 (by −13.9 ± 103.8 [p = 0.067]) from baseline to month 12, respectively. A total of 16.3% achieved HbA1c |
| وصف الملف: | application/pdf |
| تدمد: | 1744-7666 1465-6566 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6aff7d63443b8c7dbb8d5932dbbdb0Test https://doi.org/10.1080/14656566.2020.1810665Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fa6aff7d63443b8c7dbb8d5932dbbdb0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447666 14656566 |
|---|